Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1999-3-29
|
pubmed:abstractText |
CYP2D6 genotyping (CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*13, CYP2D6*16 alleles and gene duplications) was previously performed on 1053 Caucasian and African-American lung cancer cases and control individuals and no significant difference in allele frequencies between cases and control individuals detected. We have carried out additional genotyping (CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*9, CYP2D6*10, CYP2D6*17 alleles) and debrisoquine phenotyping on subgroups from this study to assess phenotype-genotype relationships. African-Americans showed significant differences from Caucasians with respect to frequency of defective CYP2D6 alleles, particularly CYP2D6*4 and CYP2D6*5. The CYP2D6*17 allele occurred at a frequency of 0.26 among 87 African-Americans and appeared to explain higher average metabolic ratios among African-Americans compared with Caucasians. CYP2D6*6, CYP2D6*8, CYP2D6*9 and CYP2D6*10 were rare in both ethnic groups but explained approximately 40% of higher than expected metabolic ratios among extensive metabolizers. Among individuals phenotyped with debrisoquine, 32 out of 359 were in the poor metabolizer range with 24 of these (75%) also showing two defective CYP2D6 alleles. Additional single strand conformational polymorphism analysis screening of samples showing large phenotype-genotype discrepancies resulted in the detection of three novel polymorphisms. If subjects taking potentially interfering drugs were excluded, this additional screening enabled the positive identification of 88% of phenotypic poor metabolizers by genotyping. This sensitivity was comparable with that of phenotyping, which identified 90% of those with two defective alleles as poor metabolizers.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0960-314X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
8
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
529-41
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9918137-African Continental Ancestry Group,
pubmed-meshheading:9918137-Base Sequence,
pubmed-meshheading:9918137-Cytochrome P-450 CYP2D6,
pubmed-meshheading:9918137-DNA Primers,
pubmed-meshheading:9918137-European Continental Ancestry Group,
pubmed-meshheading:9918137-Gene Frequency,
pubmed-meshheading:9918137-Genotype,
pubmed-meshheading:9918137-Humans,
pubmed-meshheading:9918137-Los Angeles,
pubmed-meshheading:9918137-Phenotype,
pubmed-meshheading:9918137-Polymerase Chain Reaction,
pubmed-meshheading:9918137-Polymorphism, Single-Stranded Conformational
|
pubmed:year |
1998
|
pubmed:articleTitle |
CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles.
|
pubmed:affiliation |
Department of Pharmacological Sciences, University of Newcastle upon Tyne, Medical School, UK.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|